Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.

Related Articles

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.

Acta Oncol. 2017 Nov 24;:1-4

Authors: Naqash AR, Yang LV, Sanderlin EJ, Atwell DC, Walker PR

PMID: 29171332 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2zEbvnv